Anna Rodecki

I started out in life sciences right out of college, working in technology and building the first DNA platforms when they first came out. Then I went to grad school and ended up working in the clinical space, being adjunct faculty teaching, doing my own research at the university, and at the same time having a clinic and treating patients. At some point, I transitioned to doing more research and really taking it to another level when I joined AbbVie in about 2012, 2013. That was large pharma, and that's really when working in the pharma space became the biggest portion of where I've driven a lot of patient care at volume. I'm a natural born healer, and being a physician previously, treating patients in clinic, I don't think that's ever going to go away. My treatment exposure really expanded from studying CNS (central nervous system or neurology), which was very much orthopedic-based and central nervous system-based practice, but then that grew as I ended up having more exposure, falling into oncology and working with rare diseases. I've had some opportunities, especially at AbbVie, where we were able to really make a huge difference with some really fantastic products that I supported and was part of. I continue to challenge myself in my career by really looking for those novel therapies and novel ways of discovering treatments for the human condition. Currently, I'm excited to be working in the theranostic space, which is the utilization of radioisotopes to support cancer treatment for certain cancers like gliomas that are really hard to treat surgically or with chemotherapy. It's amazing how far we've come and how quickly we have been able to achieve some of these monumental steps, and I have a lot of hope for us being able to address a lot of human conditions in the next few years.